Abstract
Hashimoto's thyroiditis (HT) is an autoimmune disease with a rising incidence. Despite years of study, its specific pathogenesis remains poorly understood. To bridge this gap, we conducted mass spectrometric analysis on thyroid tissue obtained via fine-needle aspiration from HT patients and healthy controls. We identified 44 differentially expressed proteins involved in cell adhesion, metabolism, and thyroxine synthesis. Furthermore, we developed the first patient-derived HT and papillary thyroid carcinoma (PTC) organoids as preclinical models. Our findings reveal a significant upregulation of chemokines CCL2 and CCL3 in HT organoids, highlighting their role in disease pathogenesis and providing new avenues for treatment.
Introduction
Hashimoto’s thyroiditis (HT) is the leading cause of hypothyroidism worldwide. It is characterized by the immune system's targeted attack on thyroid follicular cells, leading to chronic inflammation and tissue damage. While clinical markers like anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TGAb) antibodies are well-known, the underlying molecular mechanisms driving the disease progression are not fully elucidated.
Traditional research has relied heavily on animal models or 2D cell cultures, neither of which perfectly replicates the complex 3D architecture and immune environment of the human thyroid. This study aims to provide a high-resolution proteomic map of HT and introduce a novel 3D organoid model to better study the disease in a human context.
Methodology and Clinical Profiling
The researchers utilized a multi-omic approach starting with clinical samples. Fine-needle aspiration (FNA) was performed on 24 HT patients and 24 healthy controls. Clinical parameters, including free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH), were recorded alongside antibody levels.
The proteomic analysis involved iTRAQ labeling and LC-MS/MS. To validate these findings and create a functional model, the team developed patient-derived organoids. Thyroid tissue was dissociated and grown in a Matrigel-based 3D environment, maintaining the morphological and functional characteristics of the source tissue.
Key Insights: The Proteomic Landscape
The mass spectrometry results identified 125 significantly differentially expressed proteins (DEPs), with 44 identified as high-priority markers (26 upregulated and 18 downregulated).
Metabolic-Immune Dysregulation
Upregulated proteins, such as Annexin A6 (ANXA6) and Calreticulin (CALR), were primarily associated with immune activation and cell adhesion. In contrast, downregulated proteins were linked to critical metabolic processes, including the pentose phosphate pathway and amino acid biosynthesis. This divergence explains the dual burden of inflammation and metabolic slowdown experienced by HT patients.
The Link to Thyroid Cancer
The study observed an elevation of Galectin-3 (GAL3) in HT tissues. Since GAL3 is a known biomarker for Papillary Thyroid Carcinoma (PTC), this finding provides molecular support for the clinical observation that HT patients are at a higher risk for developing thyroid malignancies.
Organoid Models and Chemokine Signaling
A major breakthrough of this study is the creation of the first patient-derived HT organoids. These "mini-thyroids" successfully mirrored the pathological features of HT, including atypical nuclear morphology and the expression of thyroid-specific markers like PAX8 and TG.
Crucially, the organoids exhibited a massive upregulation of chemokines CCL2 and CCL3. In the organoid model, CCL3 expression was approximately eight-fold higher than in normal controls. These chemokines act as potent recruitment signals for lymphocytes, driving the characteristic immune infiltration of the thyroid gland in HT. Interestingly, many of these protein-level changes were not reflected at the mRNA level, suggesting that HT pathogenesis is heavily regulated at the translational stage.
Conclusion and Future Directions
This research provides a comprehensive proteomic signature of Hashimoto’s thyroiditis and introduces a robust human-based model for future study. The identification of the CCL2/CCL3 signaling axis offers a potential therapeutic target to mitigate the autoimmune response.
While the study is limited by sample pooling and a demographic focus on female patients, the development of HT organoids represents a significant step forward. These models can serve as a high-throughput platform for testing novel drugs aimed at preserving thyroid function and preventing progression to cancer.
Summary updated